P rotein ubiquitination controls many intracellular processes, including cell cycle progression, transcriptional activation, and signal transduction. Ubiquitination is reversible, involving enzymes that add (ubiquitin-conjugating enzymes) and remove (deubiquitinating enzymes [DUBs]) ubiquitin to and from proteins. Considerable progress has been made in the understanding of ubiquitin conjugation in nucleated cells and its role in regulating protein degradation by proteasomes. Roles for the ubiquitin-proteasome system in anucleate platelets, however, are only now being discovered.
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Yukawa et al 1, 2 were the first to demonstrate that platelets possess proteasome activity. More recent next-generation RNA-sequencing and proteomic profiling studies confirmed that platelets express key proteasomal components, 3, 4 and pharmacological inhibition or genetic disruption of the proteasome regulates megakaryocyte and platelet responses. 5, 6 Despite these advances, roles for the deubiquitination arm of the proteasome in controlling platelet function were unknown until Gupta et al 7 demonstrated in this issue of ATVB that deubiquitinase activity is essential for agonist-stimulated intracellular signal transduction and platelet responsiveness.
DUBs are cysteine proteases that specifically cleave ubiquitin from ubiquitin-conjugated protein substrates. Genome sequencing has identified 79 DUBs, making them the largest family of enzymes in the ubiquitin system. DUBs contribute to activation/deactivation, recycling and localization of numerous regulatory proteins, and thus play major roles in diverse cellular processes. DUBs are subdivided into 5 families: ubiquitin C-terminal hydrolases, ubiquitin-specific proteases, ovarian tumor proteases, Josephins and JAB1/MPN/MOV34 metalloenzymes (JAMMs; also known as MPN + and hereafter referred to as JAMM/MPN + ). 8 The ubiquitin C-terminal hydrolase, ubiquitin-specific protease, ovarian tumor protease, and Josephin families are Cys proteases, whereas the JAMM/ MPN + family members are zinc metalloproteases. Using an HA ubiquitin vinyl sulfon (HA-Ub-VS) tagging protocol, Gupta et al 7 demonstrate that platelets contain at least 10 different deubiquitinases. They also show that 2 structurally different deubiquitinase inhibitors (PYR41 and PR619), which have previously been used to study deubiquitinase pathways in the setting of cancer, 9-12 reduce deubiquitinase activity in unactivated platelets. These results demonstrate that deubiquitinases are present in platelets and provided suggestive evidence that DUBs regulate functional responses. With this information in-hand, the group proceeded to demonstrate that pharmacological inhibition of deubiquitinase activity is essential for agonist-stimulated intracellular signal transduction and platelet responsiveness. Platelets treated with general (PYR41 and PR619) and specific (b-AP15) deubiquitinase inhibitors had reduced agonist-dependent platelet aggregation, clot retraction, and integrin α 2b β 3 activation as assessed by PAC-1 binding. Deubiquitinase inhibitors also blocked platelet adhesion to collagen at high shear and time to occlusion in a FeCl 3 injury model. These results suggest that DUBs critically regulate the in vivo function of platelets at damaged arterial surfaces.
A key question is how do DUBs regulate rapid functions of platelets? To begin addressing this issue and as summarized in Figure, the authors showed that deubiquitination inhibitors blocked the phosphorylation of Akt (protein kinase B) and phosphatase and tensin homolog) in platelets stimulated with ADP, collagen, or thrombin. The exact mechanism(s) by which deubiquitinases regulate these signaling cascades requires further investigation to delineate the effects of platelet activation on deubiquitinase activity and more precisely define how DUBs control inside-out and outside-in signaling events in platelets. In regard to the latter, it will be important to evaluate the effect of DUBs on phosphoinositide 3-kinasedependent activation of integrin signaling via Rap1b and RASA3. It would also be valuable to understand the role(s) of these enzymes in megakaryocyte commitment, differentiation, and proplatelet formation, and whether DUBs influence protein degradation in developing proplatelets and circulating platelets. Regardless of the answers, the studies by Gupta et al 5, 7 add to the growing body of literature demonstrating that the ubiquitin-proteasome system is critical for megakaryocyte and platelet function, and their work provides a catalyzing platform for future growth in the area. Their results also raise important considerations for the development of deubiquitinase inhibitors as potential cancer therapeutics. 13 
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